A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial compares a three-drug inhaler called QVM149 against the combination of salmeterol and fluticasone, which my child may already be familiar with — can you help me understand how the two approaches differ and whether either might be a better fit for where my child is right now in their asthma treatment?
2. 2The trial is measuring something called 'trough FEV1,' which I understand is a lung function test taken at the lowest point before the next dose — how meaningful is that measurement for day-to-day asthma control in a teenager, and what would a meaningful change actually look like for my child?
3. 3Since this is a Phase 3 trial specifically for 12- to 17-year-olds, does that mean there's already safety and efficacy data from adults that we can look at, and how does that affect what we might expect for my child if they were to participate?
4. 4The trial isn't recruiting yet — given my child's current asthma management, does it make more sense to adjust their existing treatment now, or would it be worth waiting to see if this trial opens and whether they might be eligible to discuss with the team at that point?
5. 5QVM149 combines three medications in one inhaler — what are the known or potential risks of adding a third drug like mometasone on top of the long-acting bronchodilators, especially for a teenager whose lungs are still developing?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.